oleuropein and Bone-Diseases--Metabolic

oleuropein has been researched along with Bone-Diseases--Metabolic* in 2 studies

Trials

1 trial(s) available for oleuropein and Bone-Diseases--Metabolic

ArticleYear
Twelve-month consumption of a polyphenol extract from olive (Olea europaea) in a double blind, randomized trial increases serum total osteocalcin levels and improves serum lipid profiles in postmenopausal women with osteopenia.
    The journal of nutrition, health & aging, 2015, Volume: 19, Issue:1

    Osteoporosis is a skeletal disorder characterized by impaired bone turnover and compromised bone strength, thereby predisposing to increased risk of fracture. Preclinical research has shown that compounds produced by the olive tree (Olea europaea), may protect from bone loss, by increasing osteoblast activity at the expense of adipocyte formation. The aim of this exploratory study was to obtain a first insight on the effect of intake of an olive extract on bone turnover in postmenopausal women with decreased bone mass (osteopenia).. For that, a double blind, placebo-controlled study was performed in which participants were randomly allocated to either treatment or placebo groups.. 64 osteopenic patients, with a mean bone mineral density (BMD) T-score between -1.5 and -2.5 in the lumbar spine (L2-L4) were included in the study.. PARTICIPANTS received for 12 months daily either 250 mg/day of olive extract and 1000 mg Ca (treatment) or 1000 mg Ca alone (placebo). Primary endpoints consisted of evaluation of bone turnover markers. Secondary endpoints included BMD measurements and blood lipid profiles.. After 12 months, the levels of the pro-osteoblastic marker osteocalcin were found to significantly increase in the treatment group as compared to placebo. Simultaneously, BMD decreased in the placebo group, while remaining stable in the treatment group. In addition, improved lipid profiles were observed, with significant decrease in total- and LDL-cholesterol in the treatment group.. This exploratory study supports preclinical observations and warrants further research by showing that a specific olive polyphenol extract (Bonolive®) affects serum osteocalcin levels and may stabilize lumbar spine BMD. Moreover, the improved blood lipid profiles suggest additional health benefits associated to the intake of the olive polyphenol extract.

    Topics: Aged; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Double-Blind Method; Female; Humans; Iridoid Glucosides; Iridoids; Lipids; Lumbar Vertebrae; Middle Aged; Olea; Osteocalcin; Osteoporosis, Postmenopausal; Phytotherapy; Placebos; Plant Extracts; Polyphenols; Postmenopause; Time Factors

2015

Other Studies

1 other study(ies) available for oleuropein and Bone-Diseases--Metabolic

ArticleYear
Olive oil and its main phenolic micronutrient (oleuropein) prevent inflammation-induced bone loss in the ovariectomised rat.
    The British journal of nutrition, 2004, Volume: 92, Issue:1

    The present study was designed to evaluate the effect of olive oil and its main polyphenol (oleuropein) in ovariectomised rats with or without inflammation. Rats (6 months old) were ovariectomised or sham-operated as control. Ovariectomised rats were separated into three groups receiving different diets for 3 months: a control diet with 25 g peanut oil and 25 g rapeseed oil/kg (OVX), the control diet with 50 g olive oil/kg or the control diet with 0.15 g oleuropein/kg. The sham-operated group was given the same control diet as OVX. Inflammation was induced 3 weeks before the end of the experiment by subcutaneous injections of talc (magnesium silicate) in one-half of each group. The success of ovariectomy was verified at necropsy by the atrophy of uterine horns. Inflammation, oleuropein or olive oil intakes did not have any uterotrophic activity, as they had had no effect on uterus weight. The plasma concentration of alpha-1-acid glycoprotein (an indicator of inflammation) was increased in OVX rats with inflammation. With regard to bone variables, osteopenia in OVX was exacerbated by inflammation, as shown by a decrease in metaphyseal and total femoral mineral density. Both oleuropein and olive oil prevented this bone loss in OVX rats with inflammation. At necropsy, oleuropein and olive oil consumption had had no effect on plasma osteocalcin concentrations (marker of bone formation) or on urinary deoxypyridinoline excretion (marker of bone resorption). In conclusion, oleuropein and olive-oil feeding can prevent inflammation-induced osteopenia in OVX rats.

    Topics: Animals; Anti-Infective Agents; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Dietary Fats, Unsaturated; Female; Inflammation; Iridoid Glucosides; Iridoids; Olive Oil; Organ Size; Orosomucoid; Osteogenesis; Ovariectomy; Plant Oils; Pyrans; Rats; Rats, Wistar; Uterus

2004